News
We send the latest information from SMC Laboratories.
Amplia Therapeutics has publshed a pres releaes regarding the AMP945 and AMP886 efficacy evaluation study for NASH we have provied.
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ …
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in …
Pre-clinical studies for cirrhosis: Carbon tetrachloride (CCl4)-induced liver fibrosis
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region. W…
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection…
CohBar, Inc. announces the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesiy.
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the …
Positive control for UUO kidney fibrosis
We are excited to share with you an update about a newly established positive control – an ALK5 inhibito…
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-b Agonist ASC41
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b…
TERNS announces FDA clearance of investigational new drug application for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first…
Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH For detai…
Hepion pharma announces positive top line data for low dose CRV431 in Phase 2a "AMBITION' clinical trial for treatment of advanced NASH.
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a …